Stock Titan Trading tools for traders and investors.

-

08:57:20 PM

Last XAIR Stock Market News

XAIR - Beyond Air Inc

03/01/21 8:00 AM

Nasdaq : XAIR

Beyond Air(R) Announces Participation at Upcoming Virtual Investor Conferences in March 2021

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and

RHEA-AI

neutral

02/16/21 8:00 AM

Nasdaq : XAIR

Beyond Air(R) Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease

Award will help fund the development of high concentration nitric oxide (NO) for Nontuberculous Mycobacteria (NTM) pulmonary disease, which disproportionately affects cystic fibrosis (CF) patients Beyond Air recently initiated a pilot study using LungFit(TM) GO for at-home self-administration of up to

RHEA-AI

neutral

02/09/21 4:05 PM

Nasdaq : XAIR

Beyond Air(R) Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update

U.S. FDA reviewing premarket approval (PMA) submission for LungFit TM PH to treat persistent pulmonary hypertension of the newborn (PPHN), as Company prepares for commercialization Interim results from the acute viral pneumonia (including SARS-CoV-2) pilot study using 150 ppm nitric oxide (NO) with

RHEA-AI

positive

01/15/21 4:10 PM

Nasdaq : XAIR

Beyond Air(R) Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with

RHEA-AI

neutral

12/07/20 8:00 AM

Nasdaq : XAIR

Beyond Air(R) Initiates Patient Screening for LungFit(TM) GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in Nontuberculous Mycobacteria Lung Disease

RHEA-AI

neutral

11/19/20 8:00 AM

Nasdaq : XAIR

Beyond Air(R) to Participate in the 32nd Annual Piper Sandler Healthcare Conference from December 1-3, 2020

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and

RHEA-AI

neutral

11/11/20 4:10 PM

Nasdaq : XAIR

Beyond Air(R) Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update

Submitted a premarket approval ( PMA ) to the FDA for LungFit(TM) PH to treat persistent pulmonary hypertension of the newborn (PPHN) Expect patient enrollment to b eg i n next week for the acute viral pneumonia (including SARS-CoV-2) study; Patients will be treated with 150 ppm nitric oxide with

RHEA-AI

neutral

11/11/20 7:30 AM

Nasdaq : XAIR

Beyond Air(R) Submits Premarket Approval Application to FDA for LungFit(TM) PH to Treat Persistent Pulmonary Hypertension of the Newborn

Potential to revolutionize nitric oxide therapy by eliminating need for cumbersome cylinders creating im proved economics and safety in hospital setting Will be subject to a 180-day review period by the FDA Launch expected in 2Q 2021, pending approval GARDEN CITY, N.Y., Nov. 11, 2020 (GLOBE

RHEA-AI

neutral

10/23/20 8:00 AM

Nasdaq : XAIR

Beyond Air(R) Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients

RHEA-AI

neutral

10/21/20 7:00 AM

Nasdaq : XAIR

Beyond Air(R) Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit(TM) for the Treatment of Acute Viral Pneumonia Including COVID-19

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company

RHEA-AI

neutral